SAN DIEGO, Sept. 15, 2011 /PRNewswire/ -- Anadys
Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will
present at the UBS Global Life Sciences Conference on Tuesday, September 20, 2011 at 4:30 p.m. EDT (1:30 p.m.
PDT). The conference is being held at the Grand Hyatt
in New York. Steve Worland,
Ph.D., President and Chief Executive Officer of Anadys, will
provide an overview of Anadys and its clinical development
programs, setrobuvir and ANA773.
Dr. Worland will also present at the JMP Securities Healthcare
Conference on Tuesday, September 27,
2011 at 2:00 p.m. EDT
(11:00 a.m. PDT). The
conference is being held at the St. Regis Hotel in New York.
Each presentation will be webcast at the time of presentation
and can be accessed on the Investor Relations page of the Company's
website at www.anadyspharma.com. Listeners are encouraged to
visit the website approximately five minutes prior to each
presentation to download or install any necessary software. A
replay of the presentations will be available approximately one
hour after the live webcasts conclude and will be available through
October 4, 2011 and October 11, 2011, respectively.
About Anadys
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to improving patient care by developing novel medicines
for the treatment of hepatitis C. The Company believes
hepatitis C represents a large unmet medical need in which
meaningful improvements in treatment outcomes may be attainable
with the introduction of new medicines. Anadys is conducting
a Phase IIb study of setrobuvir, the Company's DAA, added to
pegylated interferon and ribavirin for the treatment of hepatitis
C. The Company is also developing ANA773, the Company's
oral, small-molecule inducer of endogenous interferons that acts
via the Toll like receptor 7, or TLR7, pathway in hepatitis C and
plans to initiate a Phase IIa study shortly.
Safe Harbor Statement
Statements in this press release that are not strictly
historical in nature constitute "forward-looking statements."
Such forward-looking statements involve known and unknown
risks, uncertainties and other factors, which may cause Anadys'
actual results to be materially different from historical results
or from any results expressed or implied by such forward-looking
statements. For example, the results of preclinical and early
clinical studies may not be predictive of future results, and
Anadys cannot provide any assurances that setrobuvir or ANA773 will
not have unforeseen safety issues, will have favorable results in
ongoing or future clinical trials or will receive regulatory
approval. In addition, Anadys' results may be affected by
competition from other biotechnology and pharmaceutical companies,
its effectiveness at managing its financial resources, its ability
to enter into transactions around its product candidates, its
ability to successfully develop and market products, difficulties
or delays in its non-clinical studies or clinical trials,
difficulties or delays in manufacturing its clinical trials
materials, the scope and validity of patent protection for its
products, regulatory developments and its ability to obtain
additional funding to support its operations. Risk factors
that may cause actual results to differ are more fully discussed in
Anadys' SEC filings, including Anadys' Form 10-Q for the quarter
ended June 30, 2011. All
forward-looking statements are qualified in their entirety by this
cautionary statement. Anadys is providing this information as
of this date and does not undertake any obligation to update any
forward-looking statements contained in this document as a result
of new information, future events or otherwise.
SOURCE Anadys Pharmaceuticals, Inc.